GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLM) » Definitions » Total Current Liabilities

Apollomics (Apollomics) Total Current Liabilities : $13.56 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Apollomics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Apollomics's total current liabilities for the quarter that ended in Dec. 2023 was $13.56

Apollomics Total Current Liabilities Historical Data

The historical data trend for Apollomics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics Total Current Liabilities Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Current Liabilities
12.08 13.56 12.36 13.56

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Current Liabilities Get a 7-Day Free Trial 13.56 12.80 12.36 14.14 13.56

Apollomics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Apollomics's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=9.162+4.394
+Other Current Liabilities+Current Deferred Liabilities
=-1.7763568394003E-15+0
=13.56

Apollomics's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=9.162+4.394
+Other Current Liabilities+Current Deferred Liabilities
=-1.7763568394003E-15+0
=13.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Apollomics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Apollomics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollomics (Apollomics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLM) » Definitions » Total Current Liabilities
Comparable Companies
ATHA STTK ACXP CARA TLSA ORMP IMMX CCCC GTHX GBIO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
APLMW:USA
Address
989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Website
https://www.apollomicsinc.com
Apollomics Inc is an innovative clinical-stage biotechnology company. It is is focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. It has a pipeline of 9 drug candidates across multiple programs, 6 of which are in the clinical stage of development.